Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CC-92480 + CC-93269 + Dexamethasone |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CC-92480 | CELMoD CC92480|CC 92480|Mezigdomide|BMS-986348|BMS986348|BMS 986348 | CC-92480 binds to and modulates activity of the ubiquitin E3 ligase complex member Cereblon (CRBN), which may induce ubiquitination and degradation of transcription factors in T-lymphocytes, resulting in immune system activation (Blood (2019) 134 (Supplement_1): 1812, PMID: 32130004). | ||
CC-93269 | CC 93269|CC93269|EM901|BCMAxCD3 TCB CC-93269|Alnuctamab|BMS-986349 | CD3 Antibody 99 TNFRSF17 Antibody 20 | CC-93269 is a bispecific T-cell engager (BiTE) that targets the human B-cell maturation antigen (BCMA; TNFRSF17) on tumor cells, and the CD3 antigen on cytotoxic T cell lymphocytes, potentially resulting in tumor cell killing (NCI Drug Dictionary). | |
Dexamethasone | Adexone | Desametasone |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06163898 | Phase Ib/II | CC-93269 CC-92480 + CC-93269 + Dexamethasone | A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma | Active, not recruiting | USA | ISR | 0 |